Limits...
An emptying quiver: antimicrobial drugs and resistance.

Weber JT, Courvalin P - Emerging Infect. Dis. (2005)

View Article: PubMed Central - PubMed

Affiliation: Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. jtw5@cdc.gov

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

The lack of new drug classes is a consequence of difficulties in discovery of new compounds that has persisted for many years... However, since 2000, two new drug classes have been approved by the U.S. Food and Drug Administration... Whether this trend will continue is unclear and does not obviate the need for more new classes... Articles address antimicrobial resistance in pathogens from the community, healthcare settings, and agriculture, among children and adults, and in several countries... In the case of community-associated methicillin-resistant Staphylococcus aureus (MRSA), articles cover outbreaks in Uruguay and in a US hospital nursery and maternity unit, emergence of a particular clone in Canada, prevalence in US emergency department patients, characteristics of patients admitted to a Swiss hospital, and the severity of this infection in pediatric patients... One article estimates hospitalizations associated with MRSA infection... An article on Trypanosoma brucei gambiense describes the importance and difficulty in determining resistance in parasitic infections, which can have countrywide implications for treatment, control, and use of resources... This issue does not cover resistance in malaria, gonorrhea, and HIV infection... Several articles describe the importance of the appropriate use of antimicrobial drugs as well as the difficultly of enforcement... The hope of preserving the effectiveness of existing drugs through appropriate use as well as the urgent need for the development of new drugs are both represented by the artwork featured on the cover of this issue... We hope to promote greater awareness among our readers of the strong link between antimicrobial drug use and the development of resistance and to make clear that improving use in community, healthcare, and agriculture settings, combined with other strategies, is imperative if we are to confront effectively the further development and spread of antimicrobial resistance.

Show MeSH

Related in: MedlinePlus

J. Todd Weber Dr. Weber is the director of the Office of Antimicrobial Resistance, National Center for Infectious Diseases, Centers for Disease Control and Prevention. He is responsible for coordinating antimicrobial resistance activities at CDC and co-chairs the federal Interagency Task Force on Antimicrobial Resistance. He works with other agencies, state governments, medical societies, and other public and private organizations to enhance antimicrobial resistance prevention and control, surveillance and response, applied research, and training.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3367582&req=5

Figure 2: J. Todd Weber Dr. Weber is the director of the Office of Antimicrobial Resistance, National Center for Infectious Diseases, Centers for Disease Control and Prevention. He is responsible for coordinating antimicrobial resistance activities at CDC and co-chairs the federal Interagency Task Force on Antimicrobial Resistance. He works with other agencies, state governments, medical societies, and other public and private organizations to enhance antimicrobial resistance prevention and control, surveillance and response, applied research, and training.

Mentions: Dr. Weber (Figure 2) is the director of the Office of Antimicrobial Resistance, National Center for Infectious Diseases, Centers for Disease Control and Prevention. He is responsible for coordinating antimicrobial resistance activities at CDC and co-chairs the federal Interagency Task Force on Antimicrobial Resistance. He works with other agencies, state governments, medical societies, and other public and private organizations to enhance antimicrobial resistance prevention and control, surveillance and response, applied research, and training.


An emptying quiver: antimicrobial drugs and resistance.

Weber JT, Courvalin P - Emerging Infect. Dis. (2005)

J. Todd Weber Dr. Weber is the director of the Office of Antimicrobial Resistance, National Center for Infectious Diseases, Centers for Disease Control and Prevention. He is responsible for coordinating antimicrobial resistance activities at CDC and co-chairs the federal Interagency Task Force on Antimicrobial Resistance. He works with other agencies, state governments, medical societies, and other public and private organizations to enhance antimicrobial resistance prevention and control, surveillance and response, applied research, and training.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3367582&req=5

Figure 2: J. Todd Weber Dr. Weber is the director of the Office of Antimicrobial Resistance, National Center for Infectious Diseases, Centers for Disease Control and Prevention. He is responsible for coordinating antimicrobial resistance activities at CDC and co-chairs the federal Interagency Task Force on Antimicrobial Resistance. He works with other agencies, state governments, medical societies, and other public and private organizations to enhance antimicrobial resistance prevention and control, surveillance and response, applied research, and training.
Mentions: Dr. Weber (Figure 2) is the director of the Office of Antimicrobial Resistance, National Center for Infectious Diseases, Centers for Disease Control and Prevention. He is responsible for coordinating antimicrobial resistance activities at CDC and co-chairs the federal Interagency Task Force on Antimicrobial Resistance. He works with other agencies, state governments, medical societies, and other public and private organizations to enhance antimicrobial resistance prevention and control, surveillance and response, applied research, and training.

View Article: PubMed Central - PubMed

Affiliation: Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. jtw5@cdc.gov

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

The lack of new drug classes is a consequence of difficulties in discovery of new compounds that has persisted for many years... However, since 2000, two new drug classes have been approved by the U.S. Food and Drug Administration... Whether this trend will continue is unclear and does not obviate the need for more new classes... Articles address antimicrobial resistance in pathogens from the community, healthcare settings, and agriculture, among children and adults, and in several countries... In the case of community-associated methicillin-resistant Staphylococcus aureus (MRSA), articles cover outbreaks in Uruguay and in a US hospital nursery and maternity unit, emergence of a particular clone in Canada, prevalence in US emergency department patients, characteristics of patients admitted to a Swiss hospital, and the severity of this infection in pediatric patients... One article estimates hospitalizations associated with MRSA infection... An article on Trypanosoma brucei gambiense describes the importance and difficulty in determining resistance in parasitic infections, which can have countrywide implications for treatment, control, and use of resources... This issue does not cover resistance in malaria, gonorrhea, and HIV infection... Several articles describe the importance of the appropriate use of antimicrobial drugs as well as the difficultly of enforcement... The hope of preserving the effectiveness of existing drugs through appropriate use as well as the urgent need for the development of new drugs are both represented by the artwork featured on the cover of this issue... We hope to promote greater awareness among our readers of the strong link between antimicrobial drug use and the development of resistance and to make clear that improving use in community, healthcare, and agriculture settings, combined with other strategies, is imperative if we are to confront effectively the further development and spread of antimicrobial resistance.

Show MeSH
Related in: MedlinePlus